WORX Stock Doubles As SCWorx Lands New Healthcare Deal

SCWorx Corp. stocks have been trading up by 49.63 percent following heightened investor optimism from its latest strategic developments.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading WORX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

SCWorx has secured Nasdaq Hearings Panel approval for continued listing on the Nasdaq Capital Market after previously facing delisting, regaining compliance with minimum bid price and publicly held shares requirements, aided by a recent private placement and warrant exercises.
Trading in WORX, previously suspended on Nasdaq, will be reinstated on a date to be scheduled, while the stock continues to trade on the OTCQB in the interim and will be subject to a one-year discretionary Nasdaq Panel Monitor with strict conditions and enhanced reporting requirements.
SCWorx signed a new agreement to provide healthcare supply-chain data management services to a community-owned, multi-state healthcare system serving parts of the U.S. Southwest, modestly expanding its recurring revenue customer base and reinforcing its positioning in healthcare data management.
Following the announcement of the new multi-state healthcare system agreement, WORX shares roughly doubled on very heavy volume, reflecting strong market reaction to the contract win.
For 1H 2026, SCWorx reported sharply improved gross profit, much lower net losses, reduced operating cash burn, and modest revenue growth as it emphasizes its AI-enabled healthcare supply-chain data platform and shifts toward higher-margin, recurring, multi-year contracts, while still remaining small and capital-constrained.

Live Update At 07:47:21 EDT: On Tuesday, October 20, 2026 SCWorx Corp. stock [NASDAQ: WORX] is trending up by 49.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

WORX is acting like a classic low-float momentum name wrapped around a real business turnaround story. The chart shows why traders are locked in. From late September 2026, WORX traded around the mid-$3s, printing $3.40–$4.43 closes. Then the news flow hit.

On 2026/10/06 and 2026/10/07, WORX exploded into the mid-to-high $5s, topping at $7.25 on 2026/10/06. That’s a powerful range expansion for a tiny healthcare data name. After the spike, the stock faded, with closes sliding from $5.52 on 2026/10/05 to $2.68 by 2026/10/19, showing how fast momentum traders took profits.

Intraday, the 5‑minute tape around the mid-$3s to low-$4s shows tight but active trading, with WORX repeatedly bouncing between roughly $3.65 and $4.15. That’s a consolidation band after the big run, a spot where day traders look for the next break.

More Breaking News

Fundamentals tell the other half of the story. SCWorx generated about $2.88M in revenue with roughly 40% gross margin, but net margins remain deeply negative and returns on equity are sharply below zero. Liquidity is decent with a current ratio of 2.5 and no long-term debt, yet cash flow is still slightly negative. For traders, WORX is a high-volatility, early-stage improvement story, not a finished product.

Why Traders Are Watching WORX Right Now

SCWorx has managed to do two things small caps rarely pull off at the same time: fix a listing problem and ignite price momentum. WORX was staring at a Nasdaq delisting, then secured Nasdaq Hearings Panel approval for continued listing after regaining compliance on minimum bid and public float. That win matters. A Nasdaq slot often brings better liquidity, more eyeballs, and cleaner access for active traders once trading resumes there.

The catch is that SCWorx did it by raising capital through a private placement and warrant exercises, which boosted publicly held shares above 500,000. That supports the balance sheet but also shapes float dynamics — a core piece of any WORX trading thesis. The company now sits under a one-year Panel Monitor, meaning any slip on reporting or price could snap listing risk back into focus. For short-term trading, that’s a key overhang to track.

On the business side, WORX is leaning hard into its AI-enabled healthcare supply-chain data platform. For 1H 2026, SCWorx reported higher gross profit, lower net losses, and less operating cash burn, while nudging revenue higher. The pivot toward higher-margin, recurring, multi-year contracts is exactly what traders want to see from a micro-cap SaaS-like story.

The real spark, though, was the new agreement with a community-owned, multi-state healthcare system in the U.S. Southwest. That deal modestly expands SCWorx’s recurring revenue base and, more importantly for trading, validated demand from a sizeable provider network. After the announcement, WORX roughly doubled on very heavy volume. That surge told every momentum trader scanning the market that this ticker was in play.

Conclusion

WORX is now sitting at the crossroads of story and structure. The SCWorx story is cleaner than it has been in years: Nasdaq compliance restored, trading poised to return to a major exchange, real contracts with multi-state healthcare systems, and early proof that its supply-chain data platform can generate recurring, higher-margin revenue. At the same time, the structure — tiny market cap, limited capital, heavy prior dilution, and Panel Monitor oversight — keeps WORX squarely in “speculative trading vehicle” territory.

For active traders, that mix is exactly why SCWorx stays on watchlists. The recent vertical move, where WORX doubled on massive volume after the contract announcement, shows what happens when a thin name gets a real catalyst. The sharp pullback that followed shows what happens when traders overstay the party. Both moves are lessons.

The financials back this up. SCWorx still posts negative net income and heavy loss ratios, yet it carries no long-term debt and holds over $1.26M in cash, giving it a bit of runway to keep signing healthcare customers. If WORX keeps adding multi-year deals, the revenue base can stabilize; if it stumbles, dilution risk comes right back to the front of the tape.

As Tim Sykes loves to remind traders, “You’re not here to marry stocks, you’re here to trade them.” That mindset pairs well with another key principle from modern trading education: as Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” WORX is a textbook example — a volatile, catalyst-driven small cap that rewards those who study the news, track the levels, and cut losses fast. This coverage is for educational and research purposes only, but for disciplined traders, SCWorx is a real-time case study in how news, liquidity, and charts collide.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!